A number of other brokerages have also recently commented on EPZM. Oppenheimer set a $27.00 price target on Epizyme and gave the stock a buy rating in a research report on Friday, January 4th. Cowen reaffirmed a buy rating and issued a $18.00 price objective on shares of Epizyme in a research note on Tuesday, February 26th. Leerink Swann raised Epizyme from a market perform rating to an outperform rating and set a $12.00 price objective for the company in a research note on Monday, January 7th. ValuEngine lowered Epizyme from a hold rating to a sell rating in a research note on Wednesday, January 2nd. Finally, Roth Capital reissued a buy rating on shares of Epizyme in a research note on Wednesday, February 27th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $18.90.
Shares of EPZM traded down $0.09 during trading hours on Wednesday, reaching $11.93. The stock had a trading volume of 17,499 shares, compared to its average volume of 618,456. Epizyme has a 12 month low of $5.14 and a 12 month high of $18.70. The stock has a market cap of $1.09 billion, a P/E ratio of -6.84 and a beta of 3.09.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.20. The firm had revenue of $9.70 million during the quarter, compared to the consensus estimate of $11.50 million. Analysts anticipate that Epizyme will post -2.12 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in EPZM. JGP Global Gestao de Recursos Ltda. increased its position in shares of Epizyme by 10.4% in the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 13,691 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 1,293 shares during the last quarter. Legal & General Group Plc grew its position in shares of Epizyme by 16.9% during the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,455 shares during the last quarter. American International Group Inc. grew its position in shares of Epizyme by 13.0% during the 4th quarter. American International Group Inc. now owns 39,223 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 4,513 shares during the last quarter. Exane Derivatives bought a new stake in shares of Epizyme during the 1st quarter valued at about $84,000. Finally, Quantamental Technologies LLC bought a new stake in shares of Epizyme during the 4th quarter valued at about $43,000. 72.59% of the stock is owned by institutional investors.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Featured Story: Market Capitalization
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.